Shares of Vigil Neuroscience Inc. (VIGL) are up over 240% at $7.89 today, in premarket trading on Thursday, on news of the company getting acquired by Sanofi (SNY) for a total equity value of approximately $600 million.
Vigil is developing a potential breakthrough therapy for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, or ALSP for short, a rare neurologic disorder. There are currently no approved therapies for the treatment of ALSP. The company's ALSP drug candidate, Iluzanebart, is under a phase II proof-of-concept clinical trial, dubbed IGNITE. Its second clinical asset, VG-3927, is a phase II-ready candidate being developed for the treatment of Alzheimer's disease.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.